Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Approach Yields Stable Neural Stem Cell Lines for Neuroscience Research

By LabMedica International staff writers
Posted on 27 Sep 2016
A team of neurosciences researchers developed a faster and more stable technique for establishing stable human induced neural stem cell (hiNSC) lines through the direct reprogramming of neonatal fibroblasts and adult adipose-derived stem cells.

Limited availability of human neurons poses a significant barrier to progress in biological and preclinical studies of the human nervous system. More...
Current stem cell-based approaches of neuron generation are still hindered by prolonged culture requirements, protocol complexity, and variability in neuronal differentiation.

To increase the pool of neurons for research purposes, investigators at Tufts University (Medford, MA, USA) employed direct reprogramming of neonatal fibroblasts and adult adipose-derived stem cells. According to their approach, once removed from mouse embryonic fibroblasts (MEFs) and dissociated into single-cell suspension, hiNSCs robustly differentiated into about 80%–90% betaIII-tubulin (TUJ1)-, MAP2-, and NEUN-positive neurons in as few as four days, independently of media composition.

The authors reported in the August 25, 2016, online edition of the journal Stem Cell Reports that these hiNSCs could be passaged indefinitely and cryopreserved as colonies. When injected into an early stage chicken embryo, the hiNSCs incorporated into the brain as well as the neurons of the peripheral nervous system that innervate tissues in a developing limb. Furthermore, they demonstrated the utility of these cells in co-culture with skeletal muscle as well as a three-dimensional tissue model of the human brain.

“This discovery could help reduce a significant barrier to progress in biological and in vitro studies of the human nervous system,” said senior author Dr. David L. Kaplan, professor of biomedical engineering at Tufts University. “Initial results suggest that hiNSCs are useful for future biomedical applications such as high-throughput drug assays, complex innervated co-cultures, and three dimensional models using normal and diseased cells.”

Related Links:
Tufts University



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.